Drug Overview
Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy. The product contains the same ICS/LABA components as Breo ([fluticasone furoate + vilanterol]; GlaxoSmithKline/Innoviva), plus a LAMA component, umeclidinium bromide.
GlaxoSmithKline received approval for Trelegy Ellipta in chronic obstructive pulmonary disease in Q3 2017, and is currently evaluating the drug in asthma patients whose symptoms are inadequately controlled by ICS/LABA therapies.
Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy. The product contains the same ICS/LABA components as Breo ([fluticasone furoate + vilanterol]; GlaxoSmithKline/Innoviva), plus a LAMA component, umeclidinium bromide.
GlaxoSmithKline received approval for Trelegy Ellipta in chronic obstructive pulmonary disease in Q3 2017, and is currently evaluating the drug in asthma patients whose symptoms are inadequately controlled by ICS/LABA therapies.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES